HARMONY BIOSCIENCES HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 203.67K shares, a 114.66% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 32.73K shares, a 82.28% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 115.73K shares, a 12.60% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 44.32K shares, a 66.33% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 439.61K shares, a 56.22% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 281.39K shares, a 24.34% decline from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 371.90K shares, a 51.16% decline from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 761.41K shares, a 13.85% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 203.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 396.45K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 32.73K shares 10-Q · filed 2026-05-07 | 287.66K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 115.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 439.61K shares 10-K · filed 2026-02-24 |
| 2025-09-30 | 44.32K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 426.66K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 94.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 513.96K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 184.68K shares 10-Q · filed 2025-05-06 | 451.95K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 102.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 281.39K shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 131.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | 183.13K shares derived: sum of 4 quarters · filed 2024-10-29 |
| 2024-06-30 | 32.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 63.59K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 14.12K shares 10-Q · filed 2024-04-30 | 61.72K shares derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-12-31 | 4.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 371.90K shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 12.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | 671.64K shares derived: sum of 4 quarters · filed 2023-10-31 |
| 2023-06-30 | 31.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | 838.41K shares derived: sum of 4 quarters · filed 2023-08-01 |
| 2023-03-31 | 324.30K shares 10-Q · filed 2023-05-02 | 880.28K shares derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-12-31 | 304.27K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | 761.41K shares 10-K · filed 2023-02-21 |
| 2022-09-30 | 178.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 857.36K shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 72.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | 822.63K shares derived: sum of 4 quarters · filed 2022-08-02 |
| 2022-03-31 | 205.43K shares 10-Q · filed 2022-05-03 | 872.38K shares derived: sum of 4 quarters · filed 2022-05-03 |
| 2021-12-31 | 400.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 668.78K shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 144.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 270.51K shares derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | 122.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | |
| 2021-03-31 | 1.84K shares 10-Q · filed 2021-05-11 | |
| 2020-12-31 | 1.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 37.95K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |